Compare Humana Inc (HUM) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Strategy Inc. — how do they compare? Humana Inc trades at $400 (market cap $47.81B), while Strategy Inc. trades at $100.91 (market cap $35.47B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.89% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| HUM | MSTR | |
|---|---|---|
Market Cap | $47.81B | $35.47B |
Sector | Health | Technology |
52-Week High | $409.42 | $426.40 |
52-Week Low | $163.67 | $82.31 |
Enterprise Value | $56.85B | $50.50B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
MSTR trades at $97.77, up 3.08% today, but remains in a bearish technical trend with resistance at $98. The company shows concerning fundamentals with a -2,482% net income margin and negative cash flow from operations of -$67.24M in 2025. Recent earnings missed expectations in two of the last three quarters, though analyst consensus remains bullish with a $237.63 price target representing 143% upside potential from current levels.
While Wall Street maintains a Buy rating (62% of analysts), significant risks include extreme profitability challenges, volatile earnings history, and high debt levels. The stock's valuation appears disconnected from underlying business performance, trading at a low P/E of 5.3 but extremely high P/S of 57.4, suggesting investors are pricing in future growth that current operations don't support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
